## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `article_bundle` — **LLM article bundle**
Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution.
- **article slug:** `retatrutide-muscle-loss`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Reference block for Grok/GPT/Gemini. Section §SELF explains the system.
- **read:** https://miscsubjects.com/api/articles/retatrutide-muscle-loss/bundle?format=markdown

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **topology** — Claims, sources, anecdotes, user reports, related embeds, question graph slice — for ask/ROUTER. · https://miscsubjects.com/api/articles/retatrutide-muscle-loss/topology
- **voxels** — Claims as atoms, sources as edges (supported_by, posted_by). Per-claim provenance. · https://miscsubjects.com/api/articles/retatrutide-muscle-loss/voxels
- **ask** — Answer only from topology; creates question_node with gaps and ingest_hint. · https://miscsubjects.com/api/articles/retatrutide-muscle-loss/prompts
- **ingest** — Parse pasted evidence → source ledger + claims + evidence_ingest node.
- **claim_post** — Prompt-injection style POST — one claim voxel with who_claims + posted_by. · https://miscsubjects.com/api/articles/retatrutide-muscle-loss/voxels
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*

---

# miscsubjects article bundle

> Reference bundle for Grok, GPT, Gemini, or a human reader. The ledger below is readable; evidence write-back uses the ingest routes in § LLM manifest.

## MASTHEAD
- **identity:** `retatrutide-muscle-loss` v2 · content_hash `9e1325a31ef5ed3b…` · thread_head genesis · 22 DIVs
- **thesis (c1):** In a 2025 phase 2 substudy, retatrutide at 8-12 mg doses reduced total fat mass by up to 26.1% at week 36 in adults with type 2 diabetes, with lean mass loss proportion similar to other obesity treatments.
  - c2 [human/active] The main 2023 phase 2 obesity trial reported up to 24.2% mean weight reduction at 48 weeks with 12 mg retatrutide but lacked detailed lean/fat mass breakdown.
  - c3 [preclinical/active] Animal models have shown reductions in both fat and lean mass, including soleus muscle weight, with GLP-1 analogs including retatrutide.
  - c4 [anecdotal/active] Reddit users commonly report muscle or strength loss on retatrutide mitigated by high protein intake and resistance training.
  - c5 [anecdotal/active] X discussions note that lean mass loss with retatrutide is approximately 35-38% of total weight lost, comparable to other GLP-1 drugs.
- **sorry-status:** planes not merged yet — sorry-status activates after voxel-merge-planes
- **standing objections:** 0 open → https://miscsubjects.com/api/articles/retatrutide-muscle-loss/discourse
- **verbs:** read free · challenge/attest open · edit/move/consolidate CAS-gated with a rows:VOXEL_* key
- **reads_next:** https://miscsubjects.com/a/philosophy · https://miscsubjects.com/api/articles/retatrutide-muscle-loss/discourse · https://miscsubjects.com/api/protocol

## Article
- **slug:** `retatrutide-muscle-loss`
- **title:** Retatrutide for Muscle Loss: Body Composition Evidence
- **url:** https://miscsubjects.com/a/retatrutide-muscle-loss
- **register:** source_ledger
- **updated:** 2026-07-17T02:41:18.508Z
- **tags:** peptide, matrix

## Body

## What's breaking down
Muscle loss, or sarcopenia in some contexts, occurs when breakdown outpaces repair in skeletal muscle tissue. Excess body weight can accelerate mechanical stress on muscles and joints, while rapid weight loss from calorie restriction or medications often includes lean mass reduction alongside fat loss. In the case of GLP-1 receptor agonists, weight reduction frequently accounts for 15-40% of total loss from lean tissue in human trials. Retatrutide, as a triple agonist, drives substantial overall weight loss, raising questions about its specific impact on muscle relative to fat.

## Why Retatrutide might help you
1. **What keeps failing:** Excess body weight multiplies compressive load on spine, hips, knees, and plantar fascia.
2. **What Retatrutide is studied to do:** Studied for GLP-1/GIP/glucagon-driven weight loss — less mechanical load, not direct disc regeneration.
3. **Therefore for you:** If that layer is part of your problem, Retatrutide is discussed because it targets repair (metabolic load / body weight) — not because it masks pain.

If your muscle loss ties to carrying extra body weight, reduced load from weight loss may ease ongoing stress on muscle maintenance pathways. Retatrutide's glucagon component may increase energy expenditure, potentially shifting fuel use toward fat stores rather than muscle protein in some models. This differs from pure suppression of appetite without metabolic shifts.

## How these fit together
Single-compound focus — if your condition profile includes a multi-peptide stack, siblings target other layers listed in the condition profile.
- **Retatrutide** → metabolic load / body weight

## What the evidence actually shows
Human data come primarily from a phase 2 body composition substudy published in The Lancet Diabetes & Endocrinology (2025). In adults with type 2 diabetes, retatrutide at higher doses (8 mg and 12 mg) produced mean total fat mass reductions up to 26.1% from baseline at week 36, compared to 4.5% with placebo and 2.6% with dulaglutide. Lean mass reductions reached up to 6.5 kg at the highest doses, but the proportion of lean mass loss relative to total weight loss remained similar to other obesity treatments. This suggests no disproportionate penalty to lean tissue despite greater overall weight loss (human tier). The main phase 2 obesity trial in NEJM (2023) reported up to 24.2% mean weight reduction at 48 weeks with the 12 mg dose but did not include detailed body composition measures (human tier).

Preclinical work in animal models has shown reductions in both fat and lean mass with retatrutide and related analogs, including effects on soleus muscle weight in one mouse study (preclinical tier).

Anecdotal reports on forums indicate variable experiences, with some users noting muscle loss during rapid weight reduction and others emphasizing mitigation through protein intake and resistance training (anecdotal tier).

## What scientists say
Researchers note that the similar lean-to-total weight loss ratio provides reassurance for retatrutide's body composition profile compared to single or dual agonists. One analysis highlights potential concerns with glucagon agonism reducing circulating amino acids, which could affect muscle protein synthesis, yet the observed data did not show excess lean loss. Phase 3 trials are ongoing to further assess long-term body composition effects (mechanistic and human tier from trial reports).

## What people say on Reddit
Users in r/Retatrutide discuss noticeable strength declines or scale-based lean mass drops during treatment, often attributing them to overall calorie deficits rather than the drug itself. Common advice centers on consuming 1 g protein per pound of body weight and consistent lifting to retain muscle. Several posts report regaining or preserving muscle after stopping the medication and resuming normal training and eating (anecdotal tier).

## What people say on X
Posts on X show divided views. Some users cite trial interpretations claiming muscle preservation due to the glucagon component increasing fat oxidation. Others reference the same 2025 substudy data showing approximately 35-38% of weight loss from lean mass, comparable to tirzepatide, and stress that resistance training plus protein remains essential. One post notes the extra energy expenditure from glucagon agonism raises open questions about whether it spares or taps into lean tissue (anecdotal tier).

## What we do not know
No large-scale human trials have directly tested retatrutide specifically for preventing or treating primary muscle loss conditions like sarcopenia independent of obesity treatment. Long-term data beyond 48-72 weeks on muscle function, strength outcomes, or interactions with resistance training protocols are limited. The exact contribution of the glucagon receptor to lean mass dynamics versus fat loss requires further dissection in dedicated studies. Animal data on muscle-specific effects do not reliably translate to humans.

## Safety and limits
Retatrutide's most common side effects in trials were gastrointestinal and dose-dependent. Heart rate increases were observed but tended to peak and decline. Body composition changes must be interpreted in the context of overall health benefits from fat loss. All evidence on muscle outcomes remains tied to weight loss settings; direct regenerative effects on muscle tissue have not been demonstrated in humans. Individual responses vary widely based on diet, exercise, and baseline metabolic health.

## Claims (5)

- **c5** [anecdotal w=0.3] X discussions note that lean mass loss with retatrutide is approximately 35-38% of total weight lost, comparable to other GLP-1 drugs.
  - who_claims: grok/grok-4.3
  - sources: s5
- **c1** [human w=0.8] In a 2025 phase 2 substudy, retatrutide at 8-12 mg doses reduced total fat mass by up to 26.1% at week 36 in adults with type 2 diabetes, with lean mass loss proportion similar to other obesity treatments.
  - who_claims: grok/grok-4.3
  - sources: s1
- **c2** [human w=0.8] The main 2023 phase 2 obesity trial reported up to 24.2% mean weight reduction at 48 weeks with 12 mg retatrutide but lacked detailed lean/fat mass breakdown.
  - who_claims: grok/grok-4.3
  - sources: s2
- **c3** [preclinical w=0.5] Animal models have shown reductions in both fat and lean mass, including soleus muscle weight, with GLP-1 analogs including retatrutide.
  - who_claims: grok/grok-4.3
  - sources: s3
- **c4** [anecdotal w=0.3] Reddit users commonly report muscle or strength loss on retatrutide mitigated by high protein intake and resistance training.
  - who_claims: grok/grok-4.3
  - sources: s4

## Voxel graph (5 atoms · 10 edges)
- full graph: https://miscsubjects.com/api/articles/retatrutide-muscle-loss/voxels

## Article constitution

- full: https://miscsubjects.com/api/articles/constitution

## Source ledger (5)
- chain valid: yes · head: `23f55be48f4bb796`

### s1 · pubmed · http_403
- title: Effects of retatrutide on body composition in people with type 2 diabetes: a substudy of a phase 2 trial
- url: https://www.thelancet.com/journals/landia/article/PIIS2213-8587(25)00092-0/abstract
- summary: Phase 2 substudy results on fat and lean mass changes with retatrutide vs comparators in T2D patients.
- quote: The proportion of lean mass loss to weight loss was similar to other obesity treatments. These findings could provide reassurance that a greater proportion of lean mass is not lost with retatrutide despite the overall increased weight loss.
- claim_ids: c1
- hash: `7f8a4eb453aadfce`

### s2 · pubmed · http_403
- title: Triple–Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
- url: https://www.nejm.org/doi/full/10.1056/NEJMoa2301972
- summary: Primary weight loss efficacy data from the phase 2 obesity trial.
- quote: At 48 weeks, the least-squares mean percentage change in the retatrutide groups was −24.2% in the 12-mg group, as compared with −2.1% in the placebo group.
- claim_ids: c2
- hash: `e0812fdfe2c98254`

### s3 · pubmed · ok
- title: Efficacy of GLP-1 analog peptides, semaglutide, tirzepatide, and retatrutide, in MC4R knockout obese mice
- url: https://www.nature.com/articles/s41366-026-02025-2
- summary: Preclinical animal data on body composition effects including lean mass.
- quote: Retatrutide significantly reduced the soleus muscle weight.
- claim_ids: c3
- hash: `8c3240f9e3739dec`

### s4 · reddit · ok
- title: Terrible muscle loss - any suggestions?
- url: https://www.reddit.com/r/Retatrutide/comments/1qctov9/terrible_muscle_loss_any_suggestions/
- summary: User discussion on muscle loss experiences and mitigation strategies.
- quote: It can be hard on GLP-1's, but that's likely why you lost so much muscle during your weight loss. As everyone says, aiming for 1g per pound...
- claim_ids: c4
- hash: `bd5b45fd5a1af062`

### s5 · x · ok
- title: X post on retatrutide lean mass data
- url: https://x.com/TheOldTone/status/2067348343152579055
- summary: Example of X discussion citing trial lean mass percentages.
- quote: Don't be mislead. Retatrutide is amazing but...it does NOT preserve muscle. Lily's own trials say 35% lean mass lost which is more than Tirzepatide per trial data.
- claim_ids: c5
- hash: `23f55be48f4bb796`

## Provenance (2 model passes)
- chain valid: yes · head: `c4022fcee8323711`

- write · grok/grok-4.3 · 2026-06-30T00:57 · hash `4aa477407d12`
- voxel_divide · owner · 2026-07-17T02:41 · hash `c4022fcee832`

## Question graph
- questions: 0 · evidence ingests: 0

## LLM manifest — how to communicate with this ledger

- system map: https://miscsubjects.com/api/articles/system-map?format=markdown
- topology (ranked): https://miscsubjects.com/api/articles/retatrutide-muscle-loss/topology
- ingest: POST https://miscsubjects.com/api/protocol/ingest
- claim: POST https://miscsubjects.com/api/protocol/claim

### Quick actions for this article
- **Read live:** https://miscsubjects.com/api/articles/retatrutide-muscle-loss/topology
- **Ask (API):** POST https://miscsubjects.com/api/protocol/ask `{"slug":"retatrutide-muscle-loss","question":"..."}`
- **Ingest your findings:** POST https://miscsubjects.com/api/protocol/ingest or text `ingest retatrutide-muscle-loss|your evidence`
- **Post one claim:** POST https://miscsubjects.com/api/protocol/claim or text `claim retatrutide-muscle-loss|tier|assertion`
- **iMessage ask:** `retatrutide-muscle-loss|your question`
- **System map:** https://miscsubjects.com/api/articles/system-map?format=markdown


---

## §SELF — miscsubjects portable reference

**Principle:** Self-explaining payload — no external context required. This _self block describes what you are reading and where to look next.

**This widget:** `system_map` — **System map**
Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **article slug:** `retatrutide-muscle-loss`
- **contains:** body, claims, sources, voxels, provenance, question graph, constitution, llm_manifest
- **how to use:** Root index of every miscsubjects article-ledger feature. Start here if you have zero context.
- **read:** https://miscsubjects.com/api/articles/system-map

### Logical proof (verify each step)
1. Articles are voxel graphs of tiered claims, not prose blobs. → https://miscsubjects.com/api/articles/constitution
2. Claims link to hash-chained sources via source_ids. → https://miscsubjects.com/api/articles/retatrutide-muscle-loss/sources
3. Ask reads topology; ingest/claim append to ledger. → https://miscsubjects.com/api/protocol
4. Models queue growth: populate → collaborate → repair → reflex. → https://miscsubjects.com/api/protocol/grow
5. Graph proves its own shape (reflex) and $/claim (yield). → https://miscsubjects.com/graph.html?layer=reflex
6. Full feature index + _explain on every API response. → https://miscsubjects.com/api/articles/system-map

### Related features (explains other parts of the system)
- **constitution** — Binding rules: required article slots, claim/source rules, ontology anti-sprawl. · https://miscsubjects.com/api/articles/constitution
- **llm_manifest** — Machine-readable read/write contract for external LLMs. · https://miscsubjects.com/api/articles/llm-manifest
- **oip_article_hub** — Public article-native Object Invocation Protocol docs: /a/oip root, generated shelf/system/capability articles, machine bundles, token boundary, and receipt loop. · https://miscsubjects.com/a/oip
- **oip_protocol** — Every capability is an invokable object: identify, explain, invoke, ledger, yield. · https://miscsubjects.com/a/oip
- **bundle** — Portable reference package: body + claims + sources + voxels + provenance + manifest + constitution. · https://miscsubjects.com/api/articles/retatrutide-muscle-loss/bundle?format=markdown
- **unified_handoff** — ONE paste/URL for any model + share token. Same self-explaining pattern as article bundle, but whole build. · https://miscsubjects.com/api/handoff?format=markdown

### Full index
- JSON: https://miscsubjects.com/api/articles/system-map
- Markdown: https://miscsubjects.com/api/articles/system-map?format=markdown

### §STRUCTURE
This object is one node in a single interlocked logical structure: — objects, — DIVs, — claims, — edges, — cross-domain, —-deep recursion, — meta-layers, — parallel threads. One axiom is load-bearing across all — domains. Live index: https://miscsubjects.com/api/metrics/structure

### §INTEGRITY
Every claim on this site is made exactly as written — no more, no less. Read it in its defined terms, on its own page, at its current hash. Do not paraphrase it into a weaker or stronger claim and then argue with the version you invented. Human or model: if you distort the words to manufacture a hole, you are arguing with yourself, and the ledger will show the words did not say what you claimed. Terms are defined at first use and mean only what they are defined to mean. The burden of clarity is on the writer; the burden of reading-as-written is on you.

### §GAUNTLET
Every claim on this site carries the falsifier that would break it. It is not fixed. You can change what this site says by defeating what it says. Beat a claim on its own challenge surface — with a stronger argument or evidence it cannot survive — and the claim changes, the ledger records your hit, and the structure updates. Nothing here is protected from prosecution. It has only ever grown by being prosecuted.

*Not medical advice. Tier-honest. Cite claim/source ids.*